Brokerages Anticipate Emmaus Life Sciences (NASDAQ:EMMA) to Announce ($1.20) EPS

Emmaus Life Sciences (NASDAQ:EMMA) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.

Analysts have set a 1 year consensus price target of $24.00 for the company and are forecasting that the company will post ($1.20) EPS for the current quarter, according to Zacks. Zacks has also assigned Emmaus Life Sciences an industry rank of 69 out of 256 based on the ratings given to its competitors.

Separately, Zacks Investment Research upgraded Emmaus Life Sciences from a “hold” rating to a “buy” rating and set a $6.75 price objective for the company in a research note on Tuesday, July 30th.

Shares of EMMA stock traded down $0.21 during mid-day trading on Thursday, reaching $4.51. 1,200 shares of the company’s stock traded hands, compared to its average volume of 74,419. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.19. The stock has a market cap of $230.44 million, a PE ratio of -0.40 and a beta of 2.86. Emmaus Life Sciences has a 12 month low of $3.72 and a 12 month high of $14.94.

Emmaus Life Sciences (NASDAQ:EMMA) last posted its quarterly earnings results on Friday, May 10th. The company reported ($1.62) earnings per share (EPS) for the quarter. The company had revenue of $0.46 million during the quarter. Emmaus Life Sciences had a negative return on equity of 467.46% and a negative net margin of 561.61%. On average, sell-side analysts forecast that Emmaus Life Sciences will post -5.57 earnings per share for the current fiscal year.

Emmaus Life Sciences Company Profile

Emmaus Life Sciences, Inc engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement.

Further Reading: What is a capital gains distribution?

Get a free copy of the Zacks research report on Emmaus Life Sciences (EMMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.